Research Article

Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium

Volume: 16 Number: 2 August 28, 2026
EN

Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium

Abstract

Objective: Ulcerative colitis is a relapsing inflammatory condition confined to the colonic mucosa in which persistent immune activation is accompanied by oxidative damage and epithelial disruption. This study investigated whether sodium phenylbutyrate (PBA) and suramin could mitigate these pathological changes in a mouse model of experimentally induced colitis. Materials and Methods: Following induction of colitis with dextran sulfate sodium (DSS), the efficacy of PBA and suramin was evaluated by clinical disease activity and histological scoring. Using immunohistochemical and spectrophotometric approaches, changes in proliferative activity, antioxidant enzymes, and oxidative stress indicators were analyzed. Western blot analysis was performed to assess cytokine, cyclooxygenase-2, and active caspase-3 levels together with histone 3 lysine 9 trimethylation modification; signal transducer and activator of transcription (STAT)1, STAT3, and sirtuin (SIRT) gene expression were quantified by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Results: DSS aggravated oxidative stress and inflammatory responses while suppressing proliferative activity, anti-inflammatory signaling, and antioxidant defense systems in colon tissue. Treatment with PBA or suramin partially reversed these alterations, improving redox balance and inflammatory status and modulating gene expression and histone modifications. Conclusion: These results suggest that PBA and suramin exert protective effects against DSS-induced colitis through the modulation of apoptosis, inflammation, and oxidative stress, supporting their potential therapeutic value in inflammatory bowel diseases.

Keywords

References

  1. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994 106(2): 533-9. google scholar
  2. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993 69(2): 238-49. google scholar
  3. Ono K, Nimura S, Hideshima Y, Nabeshima K, Nakashima M. Orally administered sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice. Exp Ther Med 2017 14(6): 5485-90. google scholar
  4. Korrapati MC, Shaner BE, Schnellmann RG. Recovery from glycerol-induced acute kidney injury is accelerated by suramin. J Pharmacol Exp Ther 2012 341(1): 126-36. google scholar
  5. Yan L, Gu C, Gao S, Wei B. Epigenetic regulation and therapeutic strategies in ulcerative colitis. Front Genet 2023 14: 1302886. google scholar
  6. Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol 2024 24(8): 559-76. google scholar
  7. Arda-Pirincci P, Aykol-Celik G. Galectin-1 reduces the severity of dextran sulfate sodium-induced ulcerative colitis by suppressing inflammatory and oxidative stress response. Bosn J Basic Med Sci 2020 20(3): 319-27. google scholar
  8. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG, et al. Chronic experimental colitis induced by dextran sulphate sodium is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998 114(3): 385-91. google scholar

Details

Primary Language

English

Subjects

Biochemistry and Cell Biology (Other)

Journal Section

Research Article

Publication Date

August 28, 2026

Submission Date

April 28, 2026

Acceptance Date

July 16, 2026

Published in Issue

Year 2026 Volume: 16 Number: 2

APA
Özal Coşkun, C., Karaman, E. F., Özden, S., Kaptan, E., & Arda Pirincci, P. (2026). Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium. Experimed, 16(2), 137-147. https://doi.org/10.26650/experimed.1938986
AMA
1.Özal Coşkun C, Karaman EF, Özden S, Kaptan E, Arda Pirincci P. Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium. Experimed. 2026;16(2):137-147. doi:10.26650/experimed.1938986
Chicago
Özal Coşkun, Cansu, Ecem Fatma Karaman, Sibel Özden, Engin Kaptan, and Pelin Arda Pirincci. 2026. “Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium”. Experimed 16 (2): 137-47. https://doi.org/10.26650/experimed.1938986.
EndNote
Özal Coşkun C, Karaman EF, Özden S, Kaptan E, Arda Pirincci P (August 1, 2026) Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium. Experimed 16 2 137–147.
IEEE
[1]C. Özal Coşkun, E. F. Karaman, S. Özden, E. Kaptan, and P. Arda Pirincci, “Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium”, Experimed, vol. 16, no. 2, pp. 137–147, Aug. 2026, doi: 10.26650/experimed.1938986.
ISNAD
Özal Coşkun, Cansu - Karaman, Ecem Fatma - Özden, Sibel - Kaptan, Engin - Arda Pirincci, Pelin. “Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium”. Experimed 16/2 (August 1, 2026): 137-147. https://doi.org/10.26650/experimed.1938986.
JAMA
1.Özal Coşkun C, Karaman EF, Özden S, Kaptan E, Arda Pirincci P. Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium. Experimed. 2026;16:137–147.
MLA
Özal Coşkun, Cansu, et al. “Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium”. Experimed, vol. 16, no. 2, Aug. 2026, pp. 137-4, doi:10.26650/experimed.1938986.
Vancouver
1.Cansu Özal Coşkun, Ecem Fatma Karaman, Sibel Özden, Engin Kaptan, Pelin Arda Pirincci. Role of Sodium Phenylbutyrate and Suramin in the Prevention of Ulcerative Colitis Induced by Dextran Sulfate Sodium. Experimed. 2026 Aug. 1;16(2):137-4. doi:10.26650/experimed.1938986